Veritas Pharma Inc. (the “Company”) (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), is pleased to announce that a non-brokered private placement offering of up to 9,090,910 units (“Units”) at a price of $0.22 per Unit for aggregate gross proceeds of up to $2,000,000 (the “Offering”).
Tag Archives: Cannevert Therapeutics
VANCOUVER, Aug. 10, 2016 /Weed Wire/ — Veritas Pharma Inc. announced the Company has initiated its crucial next phase of research and development, commencing functional pharmacological evaluations in rodents related to multiple cannabis strains.
VANCOUVER, Aug. 3, 2016 /Weed Wire/ — Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) is pleased to announce that through Cannevert Therapeutics Ltd, Veritas’ research arm, has developed several candidate cannabis strains and is now fully engaged in chemical and biological assessment of these key strains.
VANCOUVER, British Columbia, March 8, 2016 /Weed Wire/ — Veritas Pharma Inc. announces that it has arranged a non-brokered private placement of 2,500,000 units at a price of $0.40 per Unit for aggregate gross proceeds of $1,000,000.